Alterity Therapeutics (ATHE) Retained Earnings (2009 - 2025)

Alterity Therapeutics' Retained Earnings history runs 16 years deep, the most recent figure standing at -$153.9 million for Q4 2025.

• In Q4 2025, Retained Earnings fell 6.47% year-over-year to -$153.9 million; the TTM figure through Dec 2025 stood at -$153.9 million (down 6.47% YoY), while the FY2025 annual figure was -$144.7 million, down 2.5% from the prior year.
• Retained Earnings was -$153.9 million for Q4 2025 at Alterity Therapeutics, down from -$144.7 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $130.7 million in Q2 2021 to a low of -$153.9 million in Q4 2025.
• Historically, Retained Earnings has averaged -$109.8 million across 5 years, with a median of -$130.8 million in 2023.
• The sharpest annual moves came in 2021 and 2022: Retained Earnings surged 22923.84% in 2021, then slumped 199.68% in 2022.
• A 5-year view of Retained Earnings shows it stood at -$128.4 million in 2021, then gained by 3.13% to -$124.4 million in 2022, then declined by 5.49% to -$131.3 million in 2023, then slipped by 10.11% to -$144.5 million in 2024, then slipped by 6.47% to -$153.9 million in 2025.
• The last three Retained Earnings figures came in at -$153.9 million (Q4 2025), -$144.7 million (Q2 2025), and -$144.5 million (Q4 2024), per Business Quant data.